Ha habido 50 transacciones internas recientes registradas para Athira Pharma, Inc. (ATHA), incluyendo 35 compras y 14 ventas. El total de compras internas fue valorado en $886.53K y el total de ventas internas en $39.23K.
Internos destacados con actividad reciente incluyen Edelman Joseph, Fluke John M Jr, Johnson James A. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — ATHA
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2025-05-30 |
Edelman Joseph |
Director |
Concesión de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Fluke John M Jr |
Director |
Concesión de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Johnson James A |
Director |
Concesión de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Pickering Grant |
Director |
Concesión de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Panzara Michael A. |
Director |
Concesión de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Romano Kelly A |
Director |
Concesión de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-05-30 |
Kosacz Barbara |
Director |
Concesión de RSU |
20,900 |
$0.31 |
$6.53K |
20,900 |
| 2025-03-03 |
Litton Mark James |
President and CEO |
Concesión de RSU |
222,543 |
- |
- |
222,543 |
| 2025-03-03 |
San Martin Javier |
Chief Medical Officer |
Concesión de RSU |
74,180 |
- |
- |
74,180 |
| 2025-03-03 |
Church Kevin |
Chief Scientific Officer |
Concesión de RSU |
58,563 |
- |
- |
58,563 |
| 2025-03-03 |
Worthington Mark |
General Counsel and Cco |
Concesión de RSU |
57,263 |
- |
- |
57,263 |
| 2025-03-03 |
Renninger Robert |
SVP, Finance and Accounting |
Concesión de RSU |
39,000 |
- |
- |
39,000 |
| 2025-01-02 |
Litton Mark James |
President and CEO |
Venta Informativa |
25,107 |
$0.56 |
$14.11K |
242,591 |
| 2025-01-02 |
San Martin Javier |
Chief Medical Officer |
Venta Informativa |
10,826 |
$0.56 |
$6.08K |
35,841 |
| 2025-01-02 |
Church Kevin |
Chief Scientific Officer |
Venta Informativa |
8,510 |
$0.56 |
$4.78K |
130,761 |
| 2025-01-02 |
Worthington Mark |
General Counsel and Cco |
Venta Informativa |
8,510 |
$0.56 |
$4.78K |
83,735 |
| 2025-01-02 |
Renninger Robert |
VP of Finance |
Venta Informativa |
2,881 |
$0.56 |
$1.62K |
89,724 |
| 2024-12-31 |
Litton Mark James |
President and CEO |
Ejercicio de Opciones (Venta) |
108,333 |
- |
- |
216,667 |
| 2024-12-31 |
San Martin Javier |
Chief Medical Officer |
Ejercicio de Opciones |
46,667 |
- |
- |
46,667 |
| 2024-12-31 |
Church Kevin |
Chief Scientific Officer |
Ejercicio de Opciones (Venta) |
36,667 |
- |
- |
73,333 |
| 2024-12-31 |
Worthington Mark |
General Counsel and Cco |
Ejercicio de Opciones (Venta) |
36,667 |
- |
- |
73,333 |
| 2024-12-31 |
Renninger Robert |
VP of Finance |
Ejercicio de Opciones (Venta) |
12,359 |
- |
- |
24,718 |
| 2024-11-18 |
Church Kevin |
Chief Scientific Officer |
Concesión de RSU |
9,920 |
$0.55 |
$5.46K |
102,604 |
| 2024-11-18 |
Worthington Mark |
General Counsel and Cco |
Concesión de RSU |
3,651 |
$0.55 |
$2.01K |
55,578 |
| 2024-11-18 |
Renninger Robert |
VP of Finance |
Concesión de RSU |
3,651 |
$0.55 |
$2.01K |
80,246 |
| 2024-10-03 |
Litton Mark James |
President and CEO |
Concesión de RSU |
325,000 |
$0.45 |
$146.22K |
325,000 |
| 2024-10-03 |
Litton Mark James |
President and CEO |
Concesión de RSU |
325,000 |
$0.43 |
$138.35K |
325,000 |
| 2024-10-01 |
San Martin Javier |
Chief Medical Officer |
Concesión de RSU |
140,000 |
- |
- |
140,000 |
| 2024-10-01 |
Church Kevin |
Chief Scientific Officer |
Concesión de RSU |
110,000 |
$0.45 |
$49.49K |
110,000 |
| 2024-10-01 |
Worthington Mark |
General Counsel and Cco |
Concesión de RSU |
110,000 |
$0.45 |
$49.49K |
110,000 |
| 2024-10-01 |
Renninger Robert |
VP of Finance |
Desconocido |
74,154 |
$3.26 |
$241.74K |
- |
| 2024-10-01 |
Renninger Robert |
VP of Finance |
Concesión de RSU |
37,077 |
$0.45 |
$16.68K |
37,077 |
| 2024-09-05 |
Gengos Andrew |
CFO and Chief Business Officer |
Venta Informativa |
1,272 |
$0.57 |
$719.95 |
97,532 |
| 2024-09-05 |
Litton Mark James |
President and CEO |
Venta Informativa |
5,032 |
$0.57 |
$2.85K |
159,365 |
| 2024-09-05 |
Church Kevin |
Chief Scientific Officer |
Venta Informativa |
2,525 |
$0.57 |
$1.43K |
92,684 |
| 2024-09-05 |
Lenington Rachel |
COO and Cdo |
Venta Informativa |
2,525 |
$0.57 |
$1.43K |
20,870 |
| 2024-09-05 |
Worthington Mark |
General Counsel |
Venta Informativa |
2,525 |
$0.57 |
$1.43K |
51,927 |
| 2024-09-03 |
Gengos Andrew |
CFO and Chief Business Officer |
Concesión de RSU |
5,000 |
- |
- |
98,804 |
| 2024-09-03 |
Litton Mark James |
President and CEO |
Concesión de RSU |
20,000 |
- |
- |
164,397 |
| 2024-09-03 |
Church Kevin |
Chief Scientific Officer |
Concesión de RSU |
10,000 |
- |
- |
95,209 |
| 2024-09-03 |
Lenington Rachel |
COO and Cdo |
Concesión de RSU |
10,000 |
- |
- |
23,395 |
| 2024-09-03 |
Worthington Mark |
General Counsel |
Concesión de RSU |
10,000 |
- |
- |
54,452 |
| 2024-06-24 |
Romano Kelly A |
Director |
Compra Informativa |
27,400 |
$2.42 |
$66.18K |
80,715 |
| 2024-06-21 |
Romano Kelly A |
Director |
Compra Informativa |
15,000 |
$2.26 |
$33.87K |
53,315 |
| 2024-05-24 |
Edelman Joseph |
Director |
Concesión de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Fluke John M Jr |
Director |
Concesión de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Johnson James A |
Director |
Concesión de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Pickering Grant |
Director |
Concesión de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Panzara Michael A. |
Director |
Concesión de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
| 2024-05-24 |
Romano Kelly A |
Director |
Concesión de RSU |
20,900 |
$2.64 |
$55.18K |
20,900 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
